A 24-Week Study of the Efficacy and Safety of BLU-5937 in Adults With Refractory Chronic Cough - China Extension

Recruiting now · Phase 3 · Has a placebo group

Conditions studied: Refractory Chronic Cough

In brief

This is a randomized, double-blind, placebo-controlled, parallel-arm, Phase 3 study of BLU-5937 in participants with Refractory Chronic Cough (RCC).

Key facts

Study ID

NCT07650084

Run by

GlaxoSmithKline

People needed

75

Starts

2025-11-21

Expected to finish

2028-06-02

Last updated by the study team

2026-06-16

Who can join

Age: 18 and older, up to 80. Sex: any. Healthy volunteers: not accepted.

You may qualify if…

• Capable of giving signed informed consent
• Refractory chronic cough (including unexplained chronic cough) for at least one year
• Women of child-bearing potential must use a highly effective contraception method during the study and for at least 14 days after the last dose

You may not qualify if…

• Current smoker/vaper (all forms of smoking and inhaled substances, including, cannabis/tobacco smoke and nicotine vapors) or individuals who have given up smoking within the past 6 months, or those with >20 pack-year smoking history
• Diagnosis of chronic obstructive pulmonary disease, bronchiectasis, chronic bronchitis, cystic fibrosis, pulmonary sarcoidosis, idiopathic pulmonary fibrosis, uncontrolled asthma, or other significant or progressive airway/respiratory disorder that might affect cough based on clinician assessment
• Respiratory tract infection within 4 weeks before screening
• Laboratory confirmed Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2) infection at screening
• History of malignancy in the last 5 years
• History of alcohol or drug abuse within the last 3 years
• Has a positive serologic test for human immunodeficiency virus (HIV), hepatitis B virus surface antigen, or hepatitis C virus.
• Previous participation in a BLU-5937 trial

Where it is running

• GSK Investigational Site — Leshan, Sichuan, China (enrolling)
• GSK Investigational Site — Beijing, China (enrolling)
• GSK Investigational Site — Changsha, China (enrolling)
• GSK Investigational Site — Chengdu, China (enrolling)
• GSK Investigational Site — Chengdu, China (enrolling)
• GSK Investigational Site — Chongqing, China (enrolling)
• GSK Investigational Site — Dongguan, China (enrolling)
• GSK Investigational Site — Ganzhou, China (enrolling)
• GSK Investigational Site — Guangzhou, China (enrolling)
• GSK Investigational Site — Guangzhou, China (enrolling)
• GSK Investigational Site — Guilin, China (enrolling)
• GSK Investigational Site — Hangzhou, China (enrolling)
• GSK Investigational Site — Hefei, China (enrolling)
• GSK Investigational Site — Hefei, China (enrolling)
• GSK Investigational Site — Hohhot, China (enrolling)
• GSK Investigational Site — Huizhou, China (enrolling)
• GSK Investigational Site — Huizhou, China (enrolling)
• GSK Investigational Site — Jiangsu, China (enrolling)
• GSK Investigational Site — Jinan, China (enrolling)
• GSK Investigational Site — Kunming, China (enrolling)
• GSK Investigational Site — Liuzhou, China (enrolling)
• GSK Investigational Site — Meizhou, China (enrolling)
• GSK Investigational Site — Nanchang, China (enrolling)
• GSK Investigational Site — Pingxiang, China (enrolling)
• GSK Investigational Site — Shanghai, China (enrolling)

Full record on ClinicalTrials.gov

Trial information comes from ClinicalTrials.gov and is refreshed daily. TrialsForMe does not provide medical care and does not run the studies it lists.